2025
International perspectives on physician knowledge, attitudes, and practices related to medical cannabis
Syed S, Singh J, Elkholy H, Palavra I, Tomicevic M, Eric A, da Costa M, Guloksuz S, Radhakrishnan R. International perspectives on physician knowledge, attitudes, and practices related to medical cannabis. Frontiers In Public Health 2025, 13: 1463871. PMID: 40051509, PMCID: PMC11882600, DOI: 10.3389/fpubh.2025.1463871.Peer-Reviewed Original ResearchConceptsPhysicians' knowledgeStrength of evidenceMedical cannabisCross-sectional survey of physiciansSurvey of physiciansCross-sectional surveyYears of clinical experienceNegative health outcomesCannabis useClinical experienceRefractory chronic neuropathic painClinical decision-makingHealth outcomesPhysicians' attitudesPhysicians' willingnessChronic neuropathic painMedical use of cannabisRisk of psychosisDaily cannabis useMedication useDescriptive statisticsRisk of addictionMedical indicationsUse of cannabisPhysicians
2024
F35. INVESTIGATING GENETIC RISK FOR PSYCHOSIS IN BIPOLAR DISORDER IN INDIA USING POLYGENIC SCORES
Jeevan Y, Mahadevan J, Viswanath B, Jain S, Ganesh S, Holla B, Purushottam M, Shankarappa B, consortium A, India S. F35. INVESTIGATING GENETIC RISK FOR PSYCHOSIS IN BIPOLAR DISORDER IN INDIA USING POLYGENIC SCORES. European Neuropsychopharmacology 2024, 87: 224. DOI: 10.1016/j.euroneuro.2024.08.446.Peer-Reviewed Original ResearchPsychotic symptomsBipolar disorderPolygenic scoresGenetic susceptibility to bipolar disorderAbsence of psychotic symptomsHistory of psychotic symptomsPresence of psychotic symptomsClinical heterogeneity of BDCourse of maniaSchizophrenia polygenic scoreRisk of psychosisChronic mental disordersHeterogeneity of BDSusceptibility to bipolar disorderOdds of psychosisRisk of BDEpisodic courseBD-PRSMental disordersPsychosisIndependent dimensionsBD-1Investigate genetic riskGenetic riskManiaAttention Deficit Hyperactivity Disorder Among Youth at Clinical High Risk of Psychosis
Braun A, Liu L, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Attention Deficit Hyperactivity Disorder Among Youth at Clinical High Risk of Psychosis. Schizophrenia Bulletin Open 2024, 5: sgae028. PMID: 39583590, PMCID: PMC11584910, DOI: 10.1093/schizbullopen/sgae028.Peer-Reviewed Original ResearchClinical high riskCo-morbid ADHDClinical high risk of psychosisPredictors of transition to psychosisNorth American Prodrome Longitudinal StudySubstance useClinical high-risk individualsClinical high-risk participantsClinical high-risk youthHigh risk of psychosisAttention deficit hyperactivity disorderNegative psychotic symptomsTransition to psychosisCo-morbid disordersNon-ADHD groupRisk of psychosisDeficit hyperactivity disorderCo-morbidityIncreased substance useAssociated with numerous adverse outcomesPsychotic symptomsNumerous adverse outcomesPremorbid functioningSocial cognitionADHD group
2022
Prescription Stimulants and the Risk of Psychosis
Gallagher KE, Funaro MC, Woods SW. Prescription Stimulants and the Risk of Psychosis. Journal Of Clinical Psychopharmacology 2022, 42: 308-314. PMID: 35489031, DOI: 10.1097/jcp.0000000000001552.Peer-Reviewed Original ResearchConceptsObservational studySystematic reviewPsychosis riskCohort studyPrescription stimulantsRetrospective cohort studyProspective cohort studyCase-control studySelf-controlled case seriesInternational Prospective RegisterLongitudinal observational studyMeta-Analyses (PRISMA) guidelinesRisk of psychosisPreferred Reporting ItemsLarge-scale observational studyMPH exposureCase seriesTherapeutic dosesProspective RegisterBias assessmentEligible studiesPsychotic eventsLower riskPsychotic symptomsReporting ItemsConsensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
D’Souza D, DiForti M, Ganesh S, George TP, Hall W, Hjorthøj C, Howes O, Keshavan M, Murray RM, Nguyen TB, Pearlson GD, Ranganathan M, Selloni A, Solowij N, Spinazzola E. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. The World Journal Of Biological Psychiatry 2022, 23: 719-742. PMID: 35315315, DOI: 10.1080/15622975.2022.2038797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWFSBP Task ForceRisk of psychosisAge of exposureRates of psychosisRecurrent psychosisTask ForceEndocannabinoid systemPsychosis outcomesConsensus paperHigh riskPsychotic disordersPsychotic statesPsychosisPotency of cannabisCriteria of causalityCannabisCannabinoidsLines of evidenceCannabis lawsRiskExposureDisordersEvidenceConfoundersIllness
2020
Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity
Gibson CL, Bassir Nia A, Spriggs SA, DeFrancisco D, Swift A, Perkel C, Zhong X, Mazumdar M, Fernandez N, Patel M, Kim-Schulze S, Hurd YL. Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity. Psychiatry Research 2020, 293: 113380. PMID: 32818918, PMCID: PMC8292796, DOI: 10.1016/j.psychres.2020.113380.Peer-Reviewed Original ResearchConceptsInterleukin-6Psychosis severityCannabinoid useCannabis useIL-6 levelsCommon underlying pathologyPANSS total scoreChronic psychotic disordersRisk of psychosisPsychiatric emergency roomNegative Syndrome ScalePsychotic symptom severityInflammatory alterationsInflammatory markersInflammatory disturbancesAcute psychosisInflammatory abnormalitiesNata medicationUnderlying pathologyEmergency roomInflammatory levelsPANSS scoresPsychiatric unitUnadjusted modelsPsychotic disorders
2019
“You have to believe in something”: Risk of psychosis and psychiatrists’ beliefs in the self-fulfilling prophecy
Benoit L, Russo T, Barry C, Falissard B, Henckes N. “You have to believe in something”: Risk of psychosis and psychiatrists’ beliefs in the self-fulfilling prophecy. Social Science & Medicine 2019, 230: 20-29. PMID: 30947102, DOI: 10.1016/j.socscimed.2019.03.035.Peer-Reviewed Original Research
2018
Chapter 4 Psychotomimetic and Cognitive Effects of Δ9-Tetrahydrocannabinol in Laboratory Settings
Cahill J, Gupta S, Cortes-Briones J, Radhakrishnan R, Sherif M, D'Souza D. Chapter 4 Psychotomimetic and Cognitive Effects of Δ9-Tetrahydrocannabinol in Laboratory Settings. 2018, 75-128. DOI: 10.1016/b978-0-12-804791-0.00004-5.Peer-Reviewed Original ResearchHuman laboratory studiesCognitive effectsFunctional magnetic resonance imagingDeleterious cognitive effectsCannabis use disorderArray of outcomesPsychophysiological correlatesNeural noiseWider clinical implicationsEEG measuresRisk of psychosisΔ9-tetrahydrocannabinolUse disordersLaboratory settingPsychotic disordersMethodological strengthsClinical implicationsElectroencephalographyCannabisSchizophreniaSingle Photon Emission Computerized TomographyPhoton Emission Computerized TomographyHealthy humansPsychosisMagnetic resonance imaging
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply